伊莎妥昔单抗治疗多发性骨髓瘤的研究进展

Research progress on treatment of multiple myeloma with isatuximab-irfc

多发性骨髓瘤(MM)是一种以浆细胞恶性增殖,并通过分泌大量功能缺陷的免疫球蛋白(Ig)及其片段,同时抑制正常浆细胞增殖及Ig分泌,进而造成相关组织或器官损伤的血液系统恶性疾病。伊莎妥昔单抗是一种人工合成,可与IgG1嵌合的新型单克隆抗体药物,其与MM细胞表面的CD38受体结合后,进而通过多种机制诱导MM细胞凋亡。目前,伊莎妥昔单抗主要用于复发/难治性MM(RRMM)的治疗。笔者从伊莎妥昔单抗治疗MM的作用机制、临床疗效及药物不良反应等方面的研究新进展进行阐述。

Multiple myeloma(MM)is a hematological malignancies with plasma cell malignant proliferation,which inhibits the proliferation of normal plasma cells and the secretion of immunoglobulin(Ig)by secreting a large number of Ig and its fragments with defective functions,thus causing injury to relevant organs or tissues.Isatuximab-irfc(sarclisa)is a novel synthetic monoclonal antibody that chimeric with IgG1,which can bind to the CD38 receptor on MM cells and induce MM cell apoptosis through various mechanisms.Isetuximab-irfc is currently used for the treatment of relapsed/refractory MM(RRMM).This review elaborates on the advances in the mechanisms,clinical efficacy and adverse reactions of isatuximab-irfc in the treatment of MM.